InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,070.55
(
1.20%
)
US TECH 100
17,091.60
(
0.52%
)
Dow Jones
38,503.69
(
0.69%
)
Brent Oil
87.18
(
-0.44%
)
Bitcoin
66,291.00
(
-0.18%
)
Post# of 37
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

levelnever

Send PM Follow Ignore
Followers 265
Posts 6831
Boards Moderated 3
Alias Born 07/28/2009

levelnever

Re: None

Monday, 04/26/2010 11:02:29 PM

Monday, April 26, 2010 11:02:29 PM

Post# of 37
$15+ long-term potential - Just to give an idea of what the potential of this stock could be with current share structure if their drug Psoraxine were to make it to market. The CEO has said that Psoraxine has been approved for an FDA Phase II retrial. If it were to make it to make it past Phase II, the company has estimated that it would have a valuation of $200-$300 million, which would put the stock with current share structure in the $2-$3 range. The most similar drug on the market would be Humira by Abbott Laboratories. In 2009, Humira had $1.4 billion in sales.

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up